Cart
sales@molnova.com
10058-F4
CAS No. 403811-55-2
10058-F4( 10058-F4 | 10058F4 | 10058 F4 )
Catalog No. M14382 CAS No. 403811-55-2
10058-F4 is a specific c-Myc inhibitor that disrupts the association between the c-Myc and Max.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 44 | In Stock |
|
| 5MG | 41 | In Stock |
|
| 10MG | 65 | In Stock |
|
| 25MG | 104 | In Stock |
|
| 50MG | 154 | In Stock |
|
| 100MG | 226 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 555 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name10058-F4
-
NoteResearch use only, not for human use.
-
Brief Description10058-F4 is a specific c-Myc inhibitor that disrupts the association between the c-Myc and Max.
-
Description10058-F4 is a specific c-Myc inhibitor that disrupts the association between the c-Myc and Max, inhibits HL60 cell growth with IC50 of 51 uM; arrests AML cells at G0/G1 phase, downregulates c-Myc expression and upregulates CDK inhibitors p21 and p27; induces apoptosis through activation of mitochondrial pathway shown by downregulation of Bcl-2, upregulation of Bax, release of cytoplasmic cytochrome C, and cleavage of caspase 3, 7, and 9; also induces myeloid differentiation.
-
In Vitro——
-
In Vivo——
-
Synonyms10058-F4 | 10058F4 | 10058 F4
-
PathwayCell Cycle/DNA Damage
-
Targetc-Myc
-
Recptorc-Myc-MAX
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number403811-55-2
-
Formula Weight249.3518
-
Molecular FormulaC12H11NOS2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 41 mg/mL
-
SMILESO=C1NC(S/C1=C/C2=CC=C(CC)C=C2)=S
-
Chemical Name4-Thiazolidinone, 5-[(4-ethylphenyl)methylene]-2-thioxo-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Huang MJ, et al. Exp Hematol. 2006 Nov;34(11):1480-9.
2. Lin CP, et al. Anticancer Drugs. 2007 Feb;18(2):161-70.
3. Wang H, et al. Mol Cancer Ther. 2007 Sep;6(9):2399-408.
4. Guo J, et al. Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25.
molnova catalog
related products
-
BTYNB
BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA with IC50 of 5 uM.
-
KJ-Pyr-9
KJ-Pyr-9 is a novel small-molecule inhibitor of c-Myc (Kd=6.5 ± 1.0 nM).
-
MYCi975
MYCi975 is an orally active inhibitor of MYC.MYCi975 inhibits P493-6, MV411,SK-N-B2 cells viability in an MYC-dependent manner(IC50s of 3.7, 3.9, 6.4 μM, respectively).The initial lead, MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. However, 361 demonstrated a narrow therapeutic index.
